A Study to Assess COVID-19 Vaccination Immune Response in Multiple Sclerosis Patients Treated With Ofatumumab
Completed
Conditions studied: Multiple Sclerosis
In brief
This was a non-interventional, retrospective, observational cohort study involving the abstraction and review of pertinent data from medical records by participating physicians, who completed a customized electronic case report form hosted on the secure electronic data capture system.
Key facts
- Study ID
- NCT06460324
- Run by
- Novartis Pharmaceuticals
- People needed
- 38
- Starts
- 2022-05-20
- Expected to finish
- 2023-07-03
- Last updated by the study team
- 2024-06-14
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Aged at least 18 years of age upon receipt of first COVID-19 vaccination.
- Fully vaccinated with any FDA-authorized COVID-19 vaccination.
- Diagnosed with MS.
- Receiving ofatumumab at the time of either (or both) of the following:
- Initial COVID-19 vaccination.
- Booster vaccination.
- Had a documented measurement of humoral response at least 2 weeks after completion of either (or both) of the following:
- Full COVID-19 vaccination course.
- Booster vaccine (among patients receiving ofatumumab at the time of the booster).
You may not qualify if…
- Received treatment with monoclonal antibodies to treat or prevent COVID-19 at any time between the first COVID-19 vaccination to within 6 months of the last COVID-19 vaccination (booster-inclusive).
Where it is running
- Novartis — East Hanover, New Jersey, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.